Sign in
Taking people in United StatesNo phase

EFS of Posterior Leaflet Replacement to Reduce Mitral Regurgitation (United States)

Key facts

Who runs it
Polares Medical SA
Where
Atlanta, Cincinnati, and The Bronx, United StatesSee the 3 sites
Trial code
Status
Recruiting
People taking part
15 people, planned
Started
1 Sept 2026
Expected to end
31 Dec 2032
Type of study
Interventional
Treatments tested
  • MR-ace Implant and Delivery System
Record updated
1 September 2026

Who can take part

Age
21 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 42 criteriaShow less

Who can take part

  • Patient has symptomatic moderate-to-severe to severe functional mitral regurgitation despite stable doses of maximally tolerated guideline directed medical therapy (GDMT) per the Local Heart Team; Note: In the 30 days prior to performing screening assessments, no new GDMT medications should be introduced and current doses should be stable (i.e. no decrease of > 50% or increase of > 100%) excluding diuretics. Any changes beyond this range would not be considered stable GDMT
  • Functional MR graded 3+ or higher (using a scale of 0 to 4+) by transthoracic echocardiography (TTE) within 60 days prior to study procedure as evaluated by the sponsor's Echo Core Lab
  • New York Heart Association (NYHA) Functional Class II, III or ambulatory IV heart failure
  • Patient must present with an STS Score less than 10% and deemed by the Local Heart Team to be at high risk but operable for mitral valve surgery
  • The Local Heart Team deems the patient unsuitable for commercially approved transcatheter mitral valve therapies
  • 21 years of age or older
  • Native mitral valve geometry and size is compatible with the Polares MRace system
  • Anatomy is suitable for transfemoral transseptal access with the Polares MRace system
  • Patient is willing to participate in study and provides signed IRB/EC-approved informed consent
  • Treating physician and patient agree that patient is able to return for all required post-procedure follow-up visits
  • Patient is approved by an independent Patient Eligibility Committee

Who cannot take part

  • Previous mitral valve surgery or transcatheter mitral valve procedure
  • Prior orthotopic heart transplantation
  • Untreated Class I indication for pacing (CRT). Implant or revision of any pacing device < 30 days prior to intervention
  • Any untreated clinically significant coronary artery disease requiring revascularization. Coronary, carotid, or endovascular artery disease treated percutaneously < 30 days prior to study procedure. Cardiac surgery < 90 days prior to study procedure
  • Myocardial infarction requiring intervention < 30 days prior to study procedure
  • Active peptic ulcer or upper gastrointestinal bleeding < 90 days prior to study procedure
  • Stroke < 180 days prior to study procedure
  • Severe COPD requiring oral steroid therapy or oxygen therapy
  • Concurrent medical condition with a life expectancy of less than 2 years
  • Severe Right Ventricle (RV) dysfunction as per assessment by Local Heart Team or Eligibility Committee
  • Severe aortic stenosis or insufficiency
  • Barlow's disease
  • Active infection or endocarditis or infection requiring antibiotic therapy within 2 weeks of scheduled procedure
  • Evidence of intra-cardiac, inferior vena cava (IVC) or femoral venous thrombus. History of deep vein thrombosis (DVT) or pulmonary embolism within 6 months of the index procedure
  • Cardiogenic shock at time of enrolment. Hemodynamic instability requiring inotropic support or mechanical heart assistance
  • Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or clopidogrel, nitinol, tantalum or allergy to contrast agents that cannot be pre-medicated; Note. Patient must be able to tolerate at least one antiplatelet medication AND one anticoagulant medication
  • Severe dementia or lack of capacity due to conditions that result in either inability to provide informed consent for the trial/procedure, prevent independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up assessments
  • Patient is in need for emergent or urgent surgery for any reason or any planned cardiac surgery within the next 12 months
  • Patient is considered to be part of a vulnerable population, is under guardianship, or subject to any other medical, social or psychological conditions that preclude appropriate consent and follow-up
  • Echocardiographic parameters (any of the following, assessed by the Echo Core Lab); Left ventricular ejection fraction (LVEF) < 30%; Pulmonary artery systolic pressure (PASP) > 70mmHg or > 2/3 SBP (Systolic Blood Pressure); Left Ventricle End Diastolic Volume (LV EDV) > 200 mL; Left Ventricle End Systolic Volume (LV ESV) > 140 mL; Left Ventricle End Diastolic Diameter (LV EDD) > 70 mm; Left Ventricle End Systolic Diameter (LV ESD) > 55 mm
  • Severe renal insufficiency (creatinine > 3.0 mg/dL) or patient requiring dialysis
  • History of bleeding diathesis or coagulopathy or leukopenia (WBC < 3,000 mcL) or acute anemia (Hb < 9 g/dL) or thrombocytopenia (platelets < 50,000 cells mcL)
  • Severe tricuspid regurgitation
  • Severe mitral annulus calcification
  • Diseased mitral anterior and/or posterior leaflet, such as flail, / prolapse, or/ heavy moderate to severe calcification
  • Presence of an implanted vena cava filter or any other device (e.g. ASD closure device) that may interfere with femoral vein access or delivery system access to the mitral valve
  • Contraindication for transesophageal echocardiography (TEE) or MDCT scan
  • Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis), hypertrophic or restrictive cardiomyopathies, and constrictive pericarditis)
  • Pregnancy or breastfeeding at time of enrolment with a positive pregnancy test within 14 days of study procedure
  • Company employees or their immediate family members
  • Patient is participating in another clinical study for which follow-up is currently ongoing

Where in United States

  • Emory MidtownAtlanta, United StatesContact: Elizabeth CharlesTaking people
  • The Lindner Research Center at the Christ HospitalCincinnati, United StatesContact: Katy FischesserNot yet recruiting
  • Montefiore Medical CenterThe Bronx, United StatesContact: Tammy GuzmanNot yet recruiting

About the trial

What the trial wants to find out

The goal of this early feasibility clinical trial is to learn if the device MR-ace Implant and Delivery System works in patients with moderate or severe mitral valve regurgitation. It will also learn about the safety of the device MR-ace Implant and Delivery System. The main questions it aims to answer are:

Read full original descriptionShow less

Does implanting the MR-ace device reduce the symptoms of mitral regurgitation? Does the device reduce the the leak through your mitral valve?

Participants will:

Be implanted with the device Visit the clinic for checkups and tests at 30 days, 6 months, 12 months, and 2, 3, 4 and 5 years following your procedure Complete a quality of life survey

The group in the trial

  • TreatmentTreatment being tested

    treatment with the study device

    Treatment: MR-ace Implant and Delivery System

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Early Feasibility Experience of Posterior Leaflet Replacement to Reduce Mitral Regurgitation Using the MRace Implant (United States)
Record updated
1 September 2026